Intec Pharma Ltd (NASDAQ:NTEC) shares hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $6.33 and last traded at $6.24, with a volume of 24,289 shares changing hands. The stock had previously closed at $6.14.

Separately, Zacks Investment Research upgraded shares of Intec Pharma from a “sell” rating to a “hold” rating in a report on Thursday, June 2nd.

The firm’s 50 day moving average price is $5.24 and its 200-day moving average price is $4.32. The stock’s market capitalization is $70.86 million.

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.